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ABSTRACT 
·FK506 is a promising 
immunosuppressi ve macrolide 
antibiotic which appears highly 
effective but toxic for the treatment 
of organ graft rejection and a variety 
of autoimmune disorders. The need 
for therapeutic drug monitoring and 
individualization of dosing is 
underscored by its narrow 
therapeutic index and marked 
intersubject variability in its kinetics. 
The FKS06 dose-plasma level profile 
is quite variable and does not appear 
to be linear over the dose range of 
0.5-60 mg/day. Initially, an 
Artificial Intelligence Modelling 
System (AMIS) was used to learn 
this relationship and develop a 
dosing algorithm. Its accuracy and 
precision has been prospectively 
validated in clinical trials. 
Subsequently, we have now 
investigated the linearity of the 
relationship using a three 
dimensional (3-D) graphic method 
(SAS/Graph G3D). The surface area 
, f.of the"'noruinear plane observed was 
calculated using Design CAD 3-D. 
Our analyses indicate that FK506 is 
relatively linear over lower 
doses«lOmg/day) but shows marked 
deviation from linearity i.e. is 
nonlinear (e.g. 1.88 fold vs a linear 
fit) over the dose range of 0-50 
mg/day. We conclude that this 
novel 3-D graphical approach should 
be useful as an adjunctive population 
screening method in the drug 
development process for quantitating 
nonlinear kinetics, estimating drug 
interactions and the 3-D drug surface 
of new chemical entities. 
INTRODUCTION 
The relationship between dose 
of a drug and plasma concentration 
may be variable across the useful 
range of doses. For some drugs 
such as theophylline, this 
. relationship may be dose 
independent (linear) at low and 
moderate doses in adult patients but 
dose-dependent (nonlinear) at very 
high doses in special populations 
such as asthmatic children (1). 
Pharmacokinetic models for drug 
elimination may be subdivided into 
three major categories: 1) linear 
(first order) or dose independent in 
which the amount eliminated is 
proportional to plasma concentration; 
2) nonlinear (zero order) or dose 
dependent in which the elimination 
processes have a limited capacity 
and the amount eliminated is not 
proportional to plasma concentration 
(1vfichaelis-menton); and 3) a, 
_ <:;ombination of both, in which 
parallel pathways of elimination 
coexist. 
Several statistical and 
pharmacokinetic methods are often 
employed to assess dose 
proportionality and the linearity of 
the kinetics. The Pearson 
Correlation Coefficient and standard 
linear regression techniques assume a 
linear relationship which is not 
always the case. Compartmental 
models using nonlinear least squares 
regression and noncompartmental 
methods using statistical moment 
theory involve sophisticated 
computer algorithms and complex 
expressions that are, for the naive 
user, difficult to work with and hard 
to conceptualize. A graphical 
method which captures the linearity 
of the kinetics would be useful in 
demonstrating the dose-concentration 
relationships over the therapeutic 
range. In addition, a practical and 
quantitative system that identifies the 
... 
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subtle relationships between the dose 
gi ven a patient and the resulting 
plasma level response but does not 
require advanced mathematics to 
implement, would aid the physician 
by providing a range of doses to 
achieve the desired change in plasma 
level and thereby decrease the 
amplitude and length of time of the 
oscillations in a patient's drug levels 
before an effective and safe 
therapeutic window is achieved. 
FK506, a promising 
immunosuppressive drug used to 
control rejection in organ transplant 
recipients is very effective but toxic. 
Clinical experience has shown that it 
is critical to carefully control FK506 
plasma levels in order to balance the 
opposing risks of drug toxicity and 
allograft rejection. The ability of the 
physician to adjust drug levels and 
individualize doses is critical for the 
optimal treatment of a patient. 
Inherent dose concentration 
relationships can aid or hinder a 
physician towards this end, and 
should be considered when choosing 
the best agent for a particular 
patient. In this report, a method 
which we have termed "three 
dimensional drug surface mapping" 
will be described and used to 
delineate the dose concentration 
characteristics of FK506 in transplant 
patients. 
METHODS 
Steady-state trough FK506 
plasma levels were measured in 142 
adult heart, liver and kidney allograft 
recipients who were transplanted 
under primary FK506 
immunosuppression at the University 
of Pittsburgh medical Center during 
the time period from January 1, 1990 
to December 31, 1990. The patients 
_ jncluded in the analysis represented 
the full spectrum of functional graph 
status typical for a tertiary care 
facility. The main criteria for 
inclusion was the availability of 
consecutive doses of FK506 and 
corresponding plasma levels obtained 
after the patient had achieved steady-
state i.e. at least three days of 
administration of the current dose at 
constant intervals (e.g. every 12 
hours) and at least 24-36 hours after 
administration of a new dose (e.g. 
every 12 hours for two doses). It 
was assumed that steady-state FKS06 
levels (e.g. 2-3 x T1I2 or at least 7S-
90% of the true ess) had been 
achieved based on an average plasma 
terminal half-life in this patient 
popUlation of 8-12 hours (2). An 
open one compartment linear 
pharmacokinetic model provided a 
reasonable fit of the plasma level 
versus the time profile during 
continuous IV therapy and after oral 
doses. FKS06 concentration in 
plasma was measured by a 
3 
monoclonal antibody-based ELISA 
method as previously described (3). 
The coefficient of variation of this 
assay is 17.0% at l.4 ng/ml; 14.4% 
at 2.9 ng/ml and 12.0% at 5.7 ng/ml. 
To assess the nature of this 
relationship between the % change in 
dose and the % change in level, we 
adapted and modified a simple 
graphical technique described by 
Sarrazin et al, 1980 (1) where the % 
change in FK506 dose was plotted 
against the corresponding % change 
in FK506 plasma level at steady-
state. Dose and corresponding drug 
concentrations were then entered into 
an artificial intelligence system 
designed to "learn" the expected 
dose-plasma level relationships for 
FK506. Using the knowledge-base 
system as a model, an FK506 dosing 
algorithm was developed which 
incorporated the learned dose-plasma 
level relationships. This information 
was linked with patient factors 
known to influence clinical dosing 
decisions such as liver and renal 
function, concurrent steroids and 
rejection status. A prospective 
clinical study was then conducted 
which confimled the accuracy and 
precision of this dosing algorithm 
(4). A three-dimensional plot of the 
-learned relationships was 
implemented using a computer-
assisted drawing package 
(SAS/Graph G3D). Deviation from 
linearity (nonlinearity) in the three-
dimensional model was calculated as 
the observed increase in the surface 
area between the linear plane and the 
corresponding nonlinear plane (plane 
of best fit). The surface area of the 
nonlinear plane was calculated using 
the software package DesignCAD 3-
D, which uses surface integrals to 
make the surface area calculation 
(5). 
- . 
RESULTS 
A scattergram that depicts the 
observed relationship between a 
given FK506 dose and the 
corresponding FK506 plasma level at 
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steady-state is shown in figure 1. 
The FK506 dose-plasma level 
response profile is variable and does 
not appear to be simply linear over 
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the dose range of .5-60 mg/day. 
Repeated PK profiles consisting of 
three steady-state FK506 trough 
levels in 17 stable patients during 
maintenance therapy at 4 mg/day of 
FK506 have shown only minimal 
intrasubject variability i.e. CV of 36 
percent. This is further supported by 
the fact that the average CV in the 
FK506 assay is approximately 20 
percent. This is in sharp contrast to 
the observed wide total variability 
(inter/intrasubject) in these same 
patients i.e. CV of 91 percent. To 
determine the effect of within patient 
variability on the dose-level 
relationship, three steady state levels 
at three different doses were 
obtained for 8 patients. To 
investigate this relationship, an 
unbalanced repeated measures 
analysis with an unstructured 
covariance matrix was used (6). 
These results are consistent with our 
interpretation that the overall marked 
interpatient variability observed in 
steady-state trough levels (7 fold 
range) previously reported by 
Venkataraman, et al (2) can be 
largely explained by nonlinear 
pharmacokinetics. Furthermore, the 
significant intrasubject variability 
observed in achieved steady-state 
trough levels in patients receiving a 
range of doses i.e. 4-20 mg/day can 
also be explained by nonlinear PK. 
If FK506 exhibited simple 
linear kinetics and dose 
proportionality, the changes depicted 
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in figure 2 would be proportional 
and scattered equally about the line 
of unity. 
The relationship between 
current dose, new dose and the 
percent change in F.rC.506 level is 
shown in figure 3. It can be seen 
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that there is relative linearity in this 
system in the low dose range (dose 
< 10 mg/day). However, there is a 
rapid and disproportionate increase 
5 
in the systems response at higher 
total daily doses indicative of 
nonlinear pharmacokinetic behavior. 
Notice the disproportional increase in 
the surface area between the 
nonlinear model and a linear plane 
(figure #4). In this model the degree 
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of nonlinearity was calculated as the 
nonlinear surface area divided by the 
linear surface area and was 1.88 over 
the normal dosing range (0-50 
mg/day). This means that the 
surface area of the FK506 nonlinear 
plane of fit is 1.88 times greater than 
if it were a linear system, providing 
an index of its deviation from 
linearity. This deviation from 
linearity especially at doses above 10 , 
mg/day helps to explain why FK506 
doses can not be used alone to guide 
therapy without monitoring drug 
levels as well. 
DISCUSSION 
We have shown that the use ot 
Artificial Intelligence iVlodelling 
System (AIiVIS) can be an 
infonnative tool for understanding 
very complex, dynamic biological 
systems such as the FK506 dose 
concentration relationship. The 
accuracy and precision of the learned 
relationships derived from this 
approach have been prospectively 
confinned in clinical studies in 
transplant recipients (4). The three 
dimensional graphic representation of 
this relationship reported here 
provides a practical and quantitative 
method for characterizing the kinetic 
behavior of FK506 over a wide 
dosing range which is independent 
but complimentary to standard 
pharmacokinetic models and methods 
of analysis. We believe that this 
graphical method has significant 
clinical and regulatory implications. 
The information derived from 
this technique combined with the 
6 
FK506 dosing algorithm should be 
useful for physicians using effective 
but toxic agents like FK506 with 
known or suspected plasma drug 
level related dose-limiting toxicities. 
It should help physicians improve 
the therapeutic index or safety 
margin of these drugs by avoiding 
toxic episodes associated with high 
drug blood levels. This graphical 
method should be of special interest 
in the case of pediatric therapy with 
FK506 since children consistently 
require more than twice the total 
daily dose of FK506 compared to 
adults in order to achieve the same 
plasma level and thus are in the 
more nonlinear portion of the plane 
(7). This graphical method can also 
be envisaged in quantifying the 
change that occurs in the surface 
area of the plane when there is an 
interaction with other drugs 
(cyclosporine, ketoconazole, 
erythromycin, etc). 
In addition, this method should 
be of interest to drug developers and 
regulatory agencies who are 
concerned with the appropriate, 
expeditious and efficient 
pharmacokinetic-pharmacodynamic 
characterization of a new drug entity 
over its proposed dosing range. In 
the case for example of a promising 
new therapy for a life-threatening 
disorder i.e. AIDS, cancer, malignant 
tachyarrythmias or acute refractory 
organ rejection, it may not be ethical 
or feasible to do standard dose 
proportional studies or standard 
intense full sample phannacokinetic 
studies in the target population early 
in drug development to estimate the 
linearity of a drug's kinetics. 
However, the graphical method 
described here for FK506 requires 
only a pair of steady-state plasma 
samples for each dose level 
analyzed. It is therefore likely that 
this method could be used to' screen 
- population/observational databases to -
estimate the three-dimensional drug 
surface of a new drug entity. 
In the case of observational 
databases, this method could 
certainly generate hypotheses to be 
tested similar to what has been 
demonstrated for population 
modelling approaches such as 
NONMEM (8). In fact, it might be 
used in conjunction with these 
population methods to sort out the 
inter/intraindividual variability in the 
kinetic parameters and identify 
important covariates contributing to 
the variability. In this regard, 
attention to study design such as 
providing for intrapatient dose 
escalation would be desirable to 
facilitate the mapping of the dose-
concentration-clinical response 
surface as well. Moreover, in the 
context of randomized controlled 
studies, it could be used as an 
adjunct to standard 
7 
pharmacostatistical methods such as 
noncompartmental statistical moment 
theory for delineating dose 
proportionality and bioavailability. 
Finally, since this method provides 
an objective index of linearity over 
the useful dose range it could serve 
as a means by which drugs 
belonging to the same class might be 
compared. 
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